CY2241B1 - Fluoxetine pharmaceutical formulations - Google Patents

Fluoxetine pharmaceutical formulations

Info

Publication number
CY2241B1
CY2241B1 CY0100030A CY0100030A CY2241B1 CY 2241 B1 CY2241 B1 CY 2241B1 CY 0100030 A CY0100030 A CY 0100030A CY 0100030 A CY0100030 A CY 0100030A CY 2241 B1 CY2241 B1 CY 2241B1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical formulations
fluoxetine
dispersible tablets
formulations
appropriate
Prior art date
Application number
CY0100030A
Other languages
English (en)
Inventor
Mendizabal Arce
Original Assignee
Lilly Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8286976&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2241(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Sa filed Critical Lilly Sa
Publication of CY2241B1 publication Critical patent/CY2241B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CY0100030A 1994-07-20 2001-10-09 Fluoxetine pharmaceutical formulations CY2241B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES09401593A ES2082723B1 (es) 1994-07-20 1994-07-20 Formulacion farmaceutica de fluoxetina en forma dispersable.

Publications (1)

Publication Number Publication Date
CY2241B1 true CY2241B1 (en) 2003-07-04

Family

ID=8286976

Family Applications (1)

Application Number Title Priority Date Filing Date
CY0100030A CY2241B1 (en) 1994-07-20 2001-10-09 Fluoxetine pharmaceutical formulations

Country Status (31)

Country Link
US (1) US5747068A (el)
EP (3) EP0693281B1 (el)
JP (1) JPH0840884A (el)
KR (1) KR100360130B1 (el)
CN (2) CN1101187C (el)
AT (1) ATE200733T1 (el)
AU (2) AU692550B2 (el)
BR (1) BR9503386A (el)
CO (1) CO4410195A1 (el)
CY (1) CY2241B1 (el)
CZ (1) CZ287378B6 (el)
DE (2) DE69520768T2 (el)
DK (1) DK0693281T3 (el)
ES (2) ES2082723B1 (el)
FI (3) FI121262B (el)
GR (2) GR960300064T1 (el)
HK (1) HK1012573A1 (el)
HU (1) HU228859B1 (el)
IL (1) IL114641A (el)
MY (1) MY114776A (el)
NO (1) NO312225B2 (el)
NZ (1) NZ272610A (el)
PE (1) PE33996A1 (el)
PL (1) PL181359B1 (el)
PT (1) PT693281E (el)
RU (1) RU2145850C1 (el)
SI (1) SI0693281T1 (el)
TR (1) TR199500878A2 (el)
TW (1) TW404840B (el)
UA (1) UA41346C2 (el)
ZA (1) ZA956074B (el)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ298690B6 (cs) * 1995-12-27 2007-12-27 Tibotec Pharmaceuticals Ltd. Bioadhezivní farmaceutická kompozice, dávková forma a suchý zpusob prípravy tablet
ATE216887T1 (de) * 1996-02-29 2002-05-15 Fujisawa Pharmaceutical Co Beta-lactam-antibiotikum enthaltende tabletten und verfahren zu deren herstellung
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US5910319A (en) * 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
US5904937A (en) * 1997-10-03 1999-05-18 Fmc Corporation Taste masked pharmaceutical compositions
AU740757B2 (en) * 1997-10-09 2001-11-15 Perio Products Ltd. Delayed total release gastrointestinal drug delivery system
JP4504467B2 (ja) * 1998-07-30 2010-07-14 佐藤製薬株式会社 口腔内崩壊性錠剤
US6399101B1 (en) 2000-03-30 2002-06-04 Mova Pharmaceutical Corp. Stable thyroid hormone preparations and method of making same
PL366453A1 (en) * 2001-05-01 2005-02-07 Pfizer Products Inc. Method for manufacturing a low dose pharmaceutical composition having uniform drug distribution and potency
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
US9358214B2 (en) * 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US6645526B2 (en) 2001-11-13 2003-11-11 Mylan Pharmaceuticals, Inc. Storage stable thyroxine active drug formulations and methods for their production
US20030099699A1 (en) * 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
US20030113366A1 (en) * 2001-12-14 2003-06-19 Macgregor Alexander Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
GB2392385A (en) * 2002-09-02 2004-03-03 Cipla Ltd Pharmaceutical preparations comprising a 5HT uptake inhibitor and a homopolymer or copolymer of N-vinyl pyrrolidone
US8367111B2 (en) * 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
DE10351448A1 (de) * 2003-11-04 2005-06-09 Bayer Healthcare Ag Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften
US8747895B2 (en) * 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
CA2584957C (en) 2004-10-21 2015-08-25 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
JP4219399B2 (ja) * 2005-05-17 2009-02-04 アクテリオン ファーマシューティカルズ リミテッド 分散性錠剤
CN100353943C (zh) * 2005-07-04 2007-12-12 广州固志医药科技有限公司 乳酸氟罗沙星分散片及其制备方法
US8067451B2 (en) * 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
US20070043097A1 (en) * 2005-07-18 2007-02-22 Horizon Therapeutics, Inc. Medicaments containing famotidine and ibuprofen and administration of same
US20080020040A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Unit dose form for administration of ibuprofen
FR2891147B1 (fr) 2005-09-28 2007-12-07 Ethypharm Sa Comprimes orodispersibles de principes actifs amers
WO2007098809A1 (en) * 2006-03-03 2007-09-07 Symrise Gmbh & Co. Kg Pressed agglomerates suitable for consumption having retarded aroma release
US8067033B2 (en) 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
FR2910319B1 (fr) 2006-12-20 2011-06-03 Substipharm Dev Formulations pharmaceutiques dispersibles contenant de la fluoxetine
ES2745438T3 (es) * 2007-05-08 2020-03-02 Hercules Llc Formulación robusta de comprimidos de desintegración rápida
SG10201407965XA (en) 2009-12-02 2015-02-27 Aptalis Pharma Ltd Fexofenadine microcapsules and compositions containing them
TW201127375A (en) * 2010-01-08 2011-08-16 Eurand Inc Taste masked topiramate composition and an orally disintegrating tablet comprising the same
MX2011007675A (es) * 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
KR101438629B1 (ko) 2013-02-04 2014-09-05 현대자동차 주식회사 체결 장치 및 그 제어 방법
SI3087989T1 (sl) 2013-12-27 2019-03-29 Chugai Seiyaku Kabushiki Kaisha Trdni pripravki, ki vsebujejo tofogliflozin in postopek njihove izdelave
BR112017004694A2 (pt) * 2014-10-03 2017-12-05 Novartis Ag composições farmacêuticas compreendendo alpelisibe
CN107334742B (zh) * 2017-08-18 2020-01-31 山东力诺制药有限公司 一种盐酸氟西汀分散片及其制备方法
KR102453105B1 (ko) * 2020-10-26 2022-10-07 현대제철 주식회사 침지노즐 크리닝 장치
CN114699374B (zh) * 2022-04-01 2024-02-20 佛山市南海东方澳龙制药有限公司 一种猫犬专用盐酸氟西汀固体制剂及其制备和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3034911A (en) * 1959-03-25 1962-05-15 Nat Starch Chem Corp Tablet disintegrants
US3091574A (en) * 1961-09-05 1963-05-28 Bristol Myers Co Tablet disintegrants
DE1228029C2 (de) * 1964-05-09 1973-05-17 Merck Ag E Verfahren zur Herstellung von Tabletten durch Pressen von Pulvergemischen ohne vorhergehende Granulation
NL159577B (nl) * 1968-02-15 1979-03-15 Organon Nv Werkwijze ter bereiding van snel desintegrerende vaste vormstukken.
US3622677A (en) * 1969-07-07 1971-11-23 Staley Mfg Co A E Compressed tablets containing compacted starch as binder-disintegrant ingredient
US3852421A (en) * 1970-03-23 1974-12-03 Shinetsu Chemical Co Excipient and shaped medicaments prepared therewith
US3725556A (en) * 1970-11-12 1973-04-03 D Hanssen Method of manufacturing rapidly disintegrating pharmaceutical tablets
US4194009A (en) * 1974-01-10 1980-03-18 Eli Lilly And Company Aryloxyphenylpropylamines for obtaining a psychotropic effect
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
GB1498857A (en) * 1975-07-03 1978-01-25 Leo Ab Antidepressant composition
JPS6056659A (ja) * 1983-09-08 1985-04-02 Yanmar Diesel Engine Co Ltd 農用トラクタ−のブレ−キ装置
CH658188A5 (de) * 1984-03-23 1986-10-31 Ciba Geigy Ag Lagerstabile schnellzerfallende pharmazeutische presslinge.
GB8628359D0 (en) * 1986-11-27 1986-12-31 Zyma Sa Galenical formulation
US4844908A (en) * 1986-11-27 1989-07-04 Duphar International Research B.V. Method of preparing tablets with clovoxamine fumarate and tablets thus prepared
GB8824392D0 (en) * 1988-10-18 1988-11-23 Ciba Geigy Ag Dispersible formulation
GB8921069D0 (en) * 1989-09-18 1989-11-01 Wellcome Found Pharmaceutically active compound,preparation and use
EP0449562A3 (en) * 1990-03-29 1992-03-18 Eli Lilly And Company Use of r-fluoxetine as selective serotonin ic-receptor ligands
CA2039102A1 (en) * 1990-03-29 1991-09-30 David W. Robertson Compounds affecting serotonin receptors
US5464632C1 (en) * 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
EP0612242B1 (en) * 1991-11-15 2003-07-09 Sepracor Inc. Use of the pure s(+) isomer of fluoxetine for the preparation of a medicament against migraine headache
JPH0656659A (ja) * 1992-06-10 1994-03-01 Natl Sci Council 直接打錠できる薬学組成物及びその錠剤の製造法

Also Published As

Publication number Publication date
KR100360130B1 (ko) 2003-01-29
CN1440745A (zh) 2003-09-10
NO312225B1 (no) 2002-04-15
SI0693281T1 (en) 2001-12-31
FI953515A0 (fi) 1995-07-20
NO312225B2 (no) 2002-04-15
ES2091737T1 (es) 1996-11-16
JPH0840884A (ja) 1996-02-13
US5747068A (en) 1998-05-05
EP0693281A2 (en) 1996-01-24
EP0693281B1 (en) 2001-04-25
NZ272610A (en) 1997-08-22
AU2509895A (en) 1996-02-01
AU692550B2 (en) 1998-06-11
DE693281T1 (de) 1997-04-03
RU2145850C1 (ru) 2000-02-27
TR199500878A2 (tr) 1996-06-21
GR960300064T1 (en) 1996-11-30
HU9502154D0 (en) 1995-09-28
DK0693281T3 (da) 2001-05-21
EP1070501A1 (en) 2001-01-24
CN1440745B (zh) 2012-03-21
KR960003720A (ko) 1996-02-23
ATE200733T1 (de) 2001-05-15
NO952863L (no) 1996-01-22
IL114641A0 (en) 1995-11-27
UA41346C2 (uk) 2001-09-17
NO952863D0 (no) 1995-07-19
AU8317498A (en) 1998-11-05
HUT75036A (en) 1997-03-28
HU228859B1 (en) 2013-06-28
FI20011851A (fi) 2001-09-20
HK1012573A1 (en) 1999-08-06
MY114776A (en) 2003-01-31
CZ188095A3 (en) 1996-02-14
EP0693281A3 (en) 1996-10-30
ES2082723A1 (es) 1996-03-16
DE69520768T2 (de) 2001-08-23
PL181359B1 (pl) 2001-07-31
EP1072262A1 (en) 2001-01-31
CZ287378B6 (en) 2000-11-15
PT693281E (pt) 2001-08-30
AU707210B2 (en) 1999-07-08
CN1101187C (zh) 2003-02-12
FI121262B (fi) 2010-09-15
FI953515A (fi) 1996-01-21
TW404840B (en) 2000-09-11
CO4410195A1 (es) 1997-01-09
BR9503386A (pt) 1996-02-27
ES2082723B1 (es) 1996-10-01
CN1123142A (zh) 1996-05-29
PE33996A1 (es) 1996-09-09
PL309721A1 (en) 1996-01-22
GR3035788T3 (en) 2001-07-31
FI20011852A (fi) 2001-09-20
ES2091737T3 (es) 2001-06-01
IL114641A (en) 1999-04-11
DE69520768D1 (de) 2001-05-31
ZA956074B (en) 1996-05-14

Similar Documents

Publication Publication Date Title
HK1012573A1 (en) Fluoxetine pharmaceutical formulations
IL152659A (en) Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer
DE69905368D1 (en) Oxydiertes thymosin beta 4
EP2767291A3 (en) Treatment of glycogen storage disease type II
NZ272611A (en) The manufacturing dispersible tablets of cefaclor by direct compression
EP0744176A3 (en) Methods for inhibiting bone loss
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
HUP9902415A2 (hu) Azonnal felszabaduló szilárd beadási formák és eljárás azok előállítására
WO2001083722A3 (en) Enzymes useful for treating and methods for treating mps-vi and cells lines for producing such enzymes recombinantly
WO2003056897A3 (en) Highly phosphorylated acid beta-glucocerebrosidase and methods of treating gaucher's disease
MXPA02012957A (es) Formulacion nueva.